A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection

Trial Profile

A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2017

At a glance

  • Drugs VIS 410 (Primary)
  • Indications Influenza A virus infections
  • Focus Adverse reactions
  • Sponsors Visterra
  • Most Recent Events

    • 10 Oct 2017 This trial has been completed in Bulgaria.
    • 05 Oct 2017 According to a Visterra media release, top-line results are expected in early 2018.
    • 26 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Nov 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top